Metrics Reinforce that Clinically Guided Cannabinoid Care Contributes to Meaningful Symptom Improvement via Broadly Accepted PROMIS and PIO (Personally Important Outcome) Measures.
Latest Results are Focused on Older Adults and those in Cancer Treatment
Boston, MA – November 13, 2025 – EO Care, Inc., the leader in cannabinoid-based symptom management, released data using PROMIS* measures showing that patients leveraging its guided cannabinoid products and care platform reported meaningful improvements for pain, sleep, anxiety, and nausea/vomiting**.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
Key findings for patients over 50 include:
Key findings for cancer patients include:
Additionally, key findings from Personally Important Outcomes (PIOs), which are outcomes that a patient identified as meaningful such as walking, cooking, exercise, or playing with their grandkids, include:
“There’s a paucity of data on the effectiveness of cannabinoid care for symptom management. The power of our care platform allows us to close that gap,” said Sean Collins, CEO and co-founder of EO Care. “Millions of people, particularly the elderly and cancer patients, are turning to cannabinoid care for symptom relief, and they should have trusted, evidence-based solutions to guide their care. Our real-world data and insights provide an important window into the value of a scalable care platform that helps people find the right cannabinoid products and dosage, guided by clinical expertise.”
This data follows a 2024 cost of care analysis by the Milliman Report and commissioned by EO Care which can be found here.
These results reinforce EO Care’s commitment to providing personalized, clinically responsible cannabinoid guidance to patients. EO Care follows all HIPAA regulations. The company does not sell patient data, and only authorized clinicians and care team members can access patient records.
*PROMIS (Patient-Reported Outcomes Measurement Information System) is an NIH-developed tool for assessing physical, mental, and social health.
**Meaningful improvement is defined as a 3-point or greater reduction in the patient’s PROMIS score.
About EO Care, Inc.
EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital care platform and affordable, medicalized cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.
Media Contact: EO Care Media Relations press@eo.care
A major policy shift is reshaping how providers and payers approach symptom management. Here’s what cannabis rescheduling means for clinical care, reimbursement, and patient outcomes.
EO Care has appointed healthcare leaders William Fleming (former Humana executive) and Kristi Savacool (former Aon Hewitt CEO) to its Board of Directors, strengthening governance as cannabinoid-based symptom management enters mainstream healthcare.
The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2026 All rights reserved. Patents pending. EO Care, Inc.
